National study of ATTR heart amyloid patients on tafamidis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ATTR amyloidosis (wild-type, meaning not inherited).
- You must be 18 or older.
- A heart ultrasound or MRI must confirm that the amyloid has built up in your heart.
- You cannot have had atrial fibrillation or a serious slow heart rhythm (second- or third-degree heart block) in the past.
- If you are a woman, you must have been through menopause for at least a year before the study starts.
- You must either be taking or be a candidate for the drug tafamidis (61 mg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study looks at the long-term safety of the study drug acoramidis for people living with a heart condition called ATTR-CM. It may help doctors understand the long-term effects and benefits of this treatment.
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.